Detail Requirements. Commencing promptly upon completion of training of the Field Force Personnel that are engaged in Detailing the Product as described in Section 4.4.1 (but on the condition that Promotional Materials have been approved and delivered), Eagle shall deploy its Field Force Personnel that are engaged in Detailing to Detail the Product in accordance with the terms of this Agreement, including without limitation, the requirements for reach, frequency and position of the Product in the Detail provided in the Operating Parameters Schedule and the requirements of the then-current Sales Plan as updated from time to time. From time to time, Field Force Personnel shall organize and coordinate on the presentation of Promotional Programs as developed by the SOC and included in the then-current Sales Plan; however, except as set forth in this Agreement, without the prior written consent of TYME (not to be unreasonably withheld, delayed or conditioned), Eagle shall not conduct any Eagle Activities, other than Detailing, with respect to any Product. The Promotional Program requirements, guidelines and TYME approved speaker bureau will be provided to Eagle prior to initiation of the Promotional Programs.
Detail Requirements. (i) For the portion of the Copromotion Period ending September 30, 2008, the number of Quarterly Indevus Details, all of which shall be Primary Position Details, to be delivered to the Indevus Target Prescribers shall * during each Calendar Quarter; provided, however, that, if the period from the Effective Date to the end of the first Calendar Quarter ending after the Effective Date is less a full Calendar Quarter, the number of such Details shall be subject to pro rata adjustment to the give effect to the reduced number of days in such period. * CONFIDENTIAL TREATMENT REQUESTED
Detail Requirements. Subject to Schedule 1.40 to this Agreement, the Global Marketing Plan, and the applicable Country Marketing Plan, the Parties will develop, review and mutually agree upon appropriate Detailing efforts regarding targets, call frequency, and other sales force deployment issues in order to achieve sales objectives consistent with the forecasts developed by the GCC with input from the CCCs. Such efforts are to be reviewed and updated by the Parties at least on an annual basis. Commencing with the first Launch of the Product in the US Territory until the second anniversary of such Launch, Pfizer Sales Representatives in the US Territory will be instructed to Detail the Product in the first or second position to all prescribers who are in the top [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] percent ([CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION]%) of prescribers of antipsychotic drugs as determined by Pfizer, through the use of reputable third party data, consistent with the manner in which Pfizer makes such determinations for its own similar products (the "High Prescribers"). However, during the initial [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] after first Launch of the Product in the US Territory, such Pfizer Sales Representatives may be instructed to Detail the Product to such High Prescribers in the third position provided that such instructions are based on Pfizer's reasonable judgment that Detailing the Product in the third position would give such Detail the greatest emphasis during the particular call.
Detail Requirements. The determinations for the Calendar Year ending December 31, 2008 (“2008”) shall be mutually agreed to by the Parties by not later than June 30, 2007 provided, however, that the number of Annual Indevus Details for 2008 shall be either (i) [*]% of the number of Annual Indevus Details for the Calendar Year ending December 31, 2007 (“2007”), in which case all of the Annual Indevus Details for 2008 shall be Primary Position Details; or (ii) [*]% of the number of Annual Indevus Details for 2007, in which case all of the Annual Indevus Details for 2008 shall be Secondary Position Details; or (iii) such other allocation as may be mutually agreed to in writing by the Parties by not later than June 30, 2007.
Detail Requirements. The determinations for 2008 shall be mutually agreed to by the Parties by not later than June 30, 2007, provided that such allocation is consistent with the allocation of Annual Indevus Details set forth in Section 5.2 (a).
Detail Requirements. The Project Schedule shall, at a minimum, include the following detail and account for the following factors:
Detail Requirements. Subject to Section 7.1.5, the U.S. Commercialization Plan shall set forth the number of Primary Details and Secondary Details in respect of the Product to be performed by the Parties' Sales Representatives in the United States during each Calendar Year and the Target Prescribers for such Details (the "Detail Requirements"). Unless otherwise specified in the U.S. Commercialization Plan, each Party shall use Commercially Reasonable Efforts to perform [***] of its annual Detail Requirements in any one Calendar Quarter.
Detail Requirements
